Lucentis, which is used to treat certain eye conditions, can cause side effects. Learn about its more common, mild, and serious side effects and how to manage them.

Avastin, the anti-cancer drug already widely used off-label by physicians to treat the wet form of age-related macular degeneration, is as effective as Lucentis, the gold standard for treatment of ...

One of two Phase III studies of the drug Lucentis in patiets with diabetic macular edema met its goal, according to Genentech Inc. One of two Phase III studies of the drug Lucentis in patiets with ...

Lucentis is not known to interact with other medications, herbs, supplements, foods, or alcohol. The drug’s manufacturer didn’t look at interactions in clinical trials of Lucentis.

In DME, respondents use Lucentis in 44% and, despite lack of FDA approval for treating that condition, the specialists said they expect Eylea to erode Lucentis DME share by a third to 29%. In the US, ...

Ranibizumab, more commonly known by its brand name Lucentis, is delivered as an injection to the eye and runs about $2,023 per dose. Many patients require up to 12 injections per year.

As expected, the FDA on Friday gave its approval to Genentech to market Lucentis for wet, age-related macular degeneration. Genentech says it plans to charge $1,950 a dose for the drug, which will ...

Lucentis is not approved as a treatment for macular edema. But it is approved for another eye disease, age-related macular degeneration. So doctors can — and some already do — use the drug off ...

BOSTON - November 13, 2015 - A clinical trial among more than 300 patients has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy (PDR ...

FDA approves Coherus’ Cimerli™ (ranibizumab-eqrn) as the First and only interchangeable biosimilar to Lucentis ® for all five indications, with 12 months of interchangeability exclusivity ...

A Genentech drug to treat a vision loss disorder in an increasing number of diabetics received federal approval Friday despite critics' concerns that the South San Francisco company has promoted ...

Lucentis, known generically as ranibizumab, is the only drug approved by the Food and Drug Administration for treating the wet form of age-related macular degeneration, commonly known as AMD. But ...